Outlook Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -8.77%
- Market cap
- $107.14M
- 243.45M shares
- Filings
- 834
FY 2025−82.6% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
FY 2019derivedN/M FY19 yoy
Q3 2026N/M FY25 yoy
Q3 2026−45.9% FY25 yoy
- $107.14M
- —
- 75.8×
- —
- —
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-09-30 | $1,413,535 | reported | |
| FY 2019 | 2019-09-30 | $8,146,123 | reported | |
| FY 2018 | 2018-09-30 | $3,087,560 | reported | |
| FY 2017 | 2017-09-30 | $3,811,519 | reported | |
| FY 2016 | 2016-09-30 | $2,979,576 | reported | |
| FY 2015 | 2015-09-30 | $5,219,237 | reported |
Biological products, except diagnostic substances
Outlook Therapeutics, Inc. is the 76th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
DYAIDyadic International Inc$3.1M11.6%238.3%$14.6MALGSAligos Therapeutics, Inc.$2.2M39.5%1,106.7%$12.6MHUMAHumacyte, Inc.$2.0M—2,003.6%$165.5M
OTLKOutlook Therapeutics, Inc. (this company)$1.4M—4,416.2%$107.1M
SCNIScinai Immunotherapeutics Ltd.$1.3M99.2%633.6%$1.6MINBXInhibrx Biosciences, Inc.$1.3M550.0%10,773.5%$1.3BPLURPluri Inc.$1.0M24.0%2,344.6%$17.3MPROKProkidney Corp.$893.0K1,075.0%7,725.2%$347.7MIMAImageneBio, Inc.$800.0K77.1%5,668.6%$45.0MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR